CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers
- PMID: 26552950
- DOI: 10.1038/nrclinonc.2015.192
CHAARTED/GETUG 12--docetaxel in non-castrate prostate cancers
Comment on
-
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28. Lancet Oncol. 2015. PMID: 26028518 Clinical Trial.
-
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.N Engl J Med. 2015 Aug 20;373(8):737-46. doi: 10.1056/NEJMoa1503747. Epub 2015 Aug 5. N Engl J Med. 2015. PMID: 26244877 Free PMC article. Clinical Trial.
Similar articles
-
Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.J Urol. 2013 Dec;190(6):2094. doi: 10.1016/j.juro.2013.08.104. Epub 2013 Sep 7. J Urol. 2013. PMID: 24209521 No abstract available.
-
Words of Wisdom. Re: Androgen Deprivation Therapy plus Docetaxel and Estramustine Versus Androgen Deprivation Therapy Alone for High-risk Localised Prostate Cancer (GETUG 12): A Phase 3 Randomised Controlled Trial.Eur Urol. 2015 Dec;68(6):1098-9. doi: 10.1016/j.eururo.2015.08.047. Eur Urol. 2015. PMID: 26545569 No abstract available.
-
'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.Expert Rev Anticancer Ther. 2014 Nov;14(11):1253-6. doi: 10.1586/14737140.2014.971112. Epub 2014 Oct 29. Expert Rev Anticancer Ther. 2014. PMID: 25353342
-
Controversies in chemotherapy of prostate cancer.Front Radiat Ther Oncol. 2002;36:72-80. doi: 10.1159/000061331. Front Radiat Ther Oncol. 2002. PMID: 11842757 Review. No abstract available.
-
Chemotherapy for metastatic castrate-sensitive prostate cancer.Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44. doi: 10.1038/pcan.2016.10. Epub 2016 Mar 15. Prostate Cancer Prostatic Dis. 2016. PMID: 26976365 Review.
Cited by
-
Androgen deprivation and immunotherapy for the treatment of prostate cancer.Endocr Relat Cancer. 2017 Dec;24(12):T297-T310. doi: 10.1530/ERC-17-0145. Epub 2017 Aug 16. Endocr Relat Cancer. 2017. PMID: 28814451 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical